Oral treatment of hemophilia
AssigneesThe Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services, Virginia Tech Intellectual Properties, Inc.
InventorsOral Alpan, Tirumalai Kamala, Polly Matzinger, William Velander
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.
Claims27
A method for increasing hemostasis in a subject having hemophilia A in which clotting factor VIII (F.VIII) is deficient and wherein the subject does not have F.VIII inhibitors, comprising orally administering to the subject a therapeutically effective amount of F.VIII sufficient to induce oral tolerance and supply exogenous F.VIII to the subject, wherein the F.VIII is not present in a liposome.
A method for increasing hemostasis in a subject having hemophilia A in which clotting factor VIII (F.VIII) is deficient and wherein the subject does not have F.VIII inhibitors, consisting of orally administering to the subject a therapeutically effective amount of F.VIII and at least one pharmaceutically acceptable carrier which is not a liposome.
A method for orally administering a recombinant clotting factor VIII (F.VIII) to a subject for treatment of hemophilia A in which F.VIII is deficient, wherein the subject does not have F.VIII inhibitors, comprising orally administering a milk containing recombinant F.VIII to the subject at a therapeutically effective amount such that hemostasis in the subject is increased and oral tolerance of F.VIII is induced, thereby treating the hemophilia A.
A method for orally administering a recombinant clotting factor VIII (F.VIII) to a subject for treatment of hemophilia A in which F.VIII is deficient and wherein the subject does not have F.VIII inhibitors, comprising:
- expressing the recombinant F.VIII in a non-human mammal such that the F.VIII is expressed in milk of the mammal;
- and
- orally administering the milk in which the F.VIII has been expressed to the subject at a therapeutically effective amount such that blood clotting time in the subject is reduced and oral tolerance of the F.VIII is induced, thereby treating the hemophilia A.
A method of increasing hemostasis in a mammal having hemophilia A, comprising orally administering to the mammal 5-50 mg/kg/day of clotting factor VIII (F.VIII), wherein F.VIII is not present in a liposome, and wherein the F.VIII induces oral tolerance of the F.VIII and supplies exogenous F.VIII to the mammal, thereby increasing hemostasis in the mammal.
Dependencies are inferred from the claim text.